Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 5 de 5
2.
Article En | MEDLINE | ID: mdl-30511026

BACKGROUND: Bloating is a common symptom reported by around 16% to 31% of the general population. Functional bloating is diagnosed in patients with recurrent symptoms of bloating who do not meet the diagnostic criteria of irritable bowel syndrome or other functional gastrointestinal disorders. METHODS: This double-blind, multicentre, randomised study compared the safety and efficacy of APT036 (xyloglucan plus tyndallized Lactobacillus reuteri and Bifidobacterium brevis; Aprotecol®) and simethicone in treating functional bloating in adults. APT036 or simethicone were administered orally (3 times/day) for 20 consecutive days, with evaluations at baseline, and on Days 2, 10, 20 (end of treatment) and 30 (follow-up visit). The main outcome measure was safety. Efficacy was assessed at each visit by patient-reported symptom severity (Likert scale) and abdominal girth measurement. A hydrogen breath test was performed at baseline and Day 20. RESULTS: Both APT036 (n=54) and simethicone (n=54) were well tolerated by study subjects; no adverse effects were reported with either treatment. Compared with simethicone, APT036 significantly reduced abdominal distension (P=0.008) and flatulence (P=0.010) from baseline to Day 30. The baseline hydrogen breath test confirmed the presence of small intestinal bacterial overgrowth (SIBO) in all subjects. At Day 20, mean hydrogen gas elevation was below the threshold for a diagnosis of SIBO (<12 ppm above basal on glucose administration) in both study arms. CONCLUSIONS: Both APT036 and simethicone had good safety profiles but APT036 was superior to simethicone in relieving symptoms of functional bloating.

3.
J Gastrointestin Liver Dis ; 23(2): 215-8, 2014 Jun.
Article En | MEDLINE | ID: mdl-24949616

The prognosis of liver cirrhosis depends on the presence of its major complications as well as on other factors such as hypersplenism with thrombocytopenia. Partial splenic embolization is an effective interventional procedure performed in liver cirrhosis complicated with portal hypertension to improve the low platelet count. This technique represents an efficient alternative to splenectomy, which has major drawbacks and is associated with a high morbidity. We report a series of patients with liver cirrhosis and portal hypertension who presented with severe thrombocytopenia and were treated with partial splenic embolization eventually having a favourable outcome.


Embolization, Therapeutic/methods , Hypersplenism/therapy , Liver Cirrhosis/complications , Adult , Aged , Female , Humans , Hypersplenism/diagnostic imaging , Hypersplenism/etiology , Male , Middle Aged , Thrombocytopenia/etiology , Thrombocytopenia/therapy , Tomography, X-Ray Computed
4.
J Gastrointestin Liver Dis ; 22(2): 213-5, 2013 06.
Article En | MEDLINE | ID: mdl-23799222

Budd Chiari syndrome or hepatic venous outflow obstruction is a complex entity with multiple etiologies and various clinical manifestations. It is often difficult to establish the diagnosis. The most common cause is a hypercoagulable state due to either genetic disorders of blood coagulation or several acquired conditions such as hematological diseases, tumors, infections, chronic inflammatory diseases, pregnancy. The most common clinical presentation is hepatomegaly, abdominal pain and ascites, but the onset can also be dramatical and life threatening with upper digestive bleeding due to portal hypertension through postsinusoidal blockage. We report the case of a young patient with a coagulation disorder secondary to a mutation of factor V Leiden, who presented with upper digestive bleeding as the first manifestation of Budd Chiari syndrome and who also was associated with myocardial infarction in his past medical history.


Blood Coagulation Disorders, Inherited/complications , Blood Coagulation/genetics , Budd-Chiari Syndrome/etiology , Factor V/genetics , Gastrointestinal Hemorrhage/etiology , Hypertension, Portal/etiology , Mutation , Adult , Anticoagulants/therapeutic use , Blood Coagulation/drug effects , Blood Coagulation Disorders, Inherited/blood , Blood Coagulation Disorders, Inherited/diagnosis , Blood Coagulation Disorders, Inherited/drug therapy , Blood Coagulation Disorders, Inherited/genetics , Budd-Chiari Syndrome/blood , Budd-Chiari Syndrome/diagnosis , Budd-Chiari Syndrome/drug therapy , DNA Mutational Analysis , Humans , Hypertension, Portal/diagnosis , Male , Predictive Value of Tests , Treatment Outcome , Ultrasonography, Doppler, Color
5.
J Gastrointestin Liver Dis ; 15(1): 57-9, 2006 Mar.
Article En | MEDLINE | ID: mdl-16680234

Langerhans'cell histiocytosis (Histiocytosis X) is a rare disease of unknown cause characterized by oligoclonal proliferation of Langerhans cells. It occurs mostly in children and young adults and involves one or more body systems such as bone, hypothalamus, posterior pituitary gland, lymph nodes, liver or various soft tissues. The diagnosis is always made by a histological approach. We report a case of Langerhans'cell histiocytosis in a young patient with clinical signs of diabetes insipidus and hepatic involvement in whom the immunohistochemical analysis of the liver tissue led to the definitive diagnosis.


Histiocytosis, Langerhans-Cell/pathology , Liver Diseases/etiology , Liver Diseases/pathology , Adult , Diabetes Insipidus/etiology , Granuloma/etiology , Granuloma/pathology , Histiocytosis, Langerhans-Cell/complications , Humans , Male
...